Jaap Oostendorp

Moderna Therapeutics (United States) — United States

Immunology and Microbiology · Life Sciences

23h-index4.1kcitations65works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(25), Cervical Cancer and HPV Research(15), Immune Response and Inflammation(8), Receptor Mechanisms and Signaling(8), Cancer Immunotherapy and Biomarkers(7)

Publications65 total

An mRNA influenza vaccine induces immunity comparable to an adjuvanted vaccine in a randomized trial
npj Vaccines·2026Open Access
P-1452. A Seasonal Influenza Hemagglutinin mRNA-Based Vaccine Induces Humoral and Cellular Immunity Comparable to an Adjuvanted Inactivated Influenza Virus Vaccine
Open Forum Infectious Diseases·2026Open Access
P-1453. Characterization of longitudinal humoral and cellular immunogenicity following 2 or 3 doses of an mRNA-based cytomegalovirus vaccine in healthy adults
Open Forum Infectious Diseases·2026Open Access
P-1454. mRNA-Based Respiratory Syncytial Virus Vaccine mRNA-1345 Induces Robust, Polyfunctional, and Durable CD4+ and CD8+ T Cell Responses with Similar Features in Adults Across Age Groups
Open Forum Infectious Diseases·2026Open Access
P-1505. Cellular and Humoral Immunogenicity of 1 or 2 injections of mRNA-1403, a Multivalent Norovirus mRNA Vaccine, in Healthy Adults
Open Forum Infectious Diseases·2026Open Access
mRNA-1010 influenza vaccine elicits distinct and enhanced humoral immunity compared to adjuvanted inactivated vaccines
npj Vaccines·2025Open Access
An mRNA-based cytomegalovirus vaccine induces robust T-cell immune responses in cytomegalovirus-seropositive adults who have undergone allogeneic hematopoietic cell transplantation
Blood·2025
Tracking Inflammation in Real Time Following Vaccination: Validation of a Novel Individualized Digital Inflammatory Biomarker Relative to Serum Biomarkers
2025Open Access
575. Safety and Immunogenicity of mRNA-1403, a Multivalent Norovirus mRNA Vaccine, in Healthy Adults: Interim Results of a Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial
Open Forum Infectious Diseases·2025· 3 citedOpen Access
Data from Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response
2023Open Access
Supplementary Materials from Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response
2023Open Access
Data from Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response
2023Open Access
Supplementary Materials from Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response
2023Open Access
Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine
Clinical Immunology·2019· 25 citedOpen Access
A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema
QJM·2016· 100 citedOpen Access
Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response
Clinical Cancer Research·2016· 163 cited
TNF-α and IL-1β-activated human mesenchymal stromal cells increase airway epithelial wound healing in vitro via activation of the epidermal growth factor receptor
Respiratory Research·2016· 96 citedOpen Access
Effects of autologous mesenchymal stromal cell treatment for severe emphysema on lung tissue: A clinical trial
2015
Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma
Cancer Immunology Immunotherapy·2015· 17 citedOpen Access
CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses
Biomaterials·2014· 265 cited
page 1 of 4Next →

Frequent Co-authors

Sjoerd H. van der Burg(25), Marij J.P. Welters(18), A. Rob P.M. Valentijn(18), Gemma G. Kenter(14), Lorraine M. Fathers(13), Jan W. Drijfhout(13), Cornelis J.M. Melief(13), Hans W. Nijman(10), Dorien M. A. Berends-van der Meer(8), Gert Jan Fleuren(8), Toos Daemen(8), Harry Hollema(8), Cornelis J.M. Melief(8), Margriet J. Löwik(7), Mariëtte I.E. van Poelgeest(7), Renee Vermeij(7), Nikki M. Loof(7), Bart W.J. Hellebrekers(7), Margriet J.G. Löwik(6), Linda F. M. Stynenbosch(6)